Drug Profile
Research programme: oral T-cell vaccines - VAXIMM
Alternative Names: VXM 10m; VXM 10maLatest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator VAXIMM
- Class Antineoplastics; Cancer vaccines
- Mechanism of Action Angiogenesis inhibitors; Immunostimulants; Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for preclinical development in Cancer in Germany (PO)
- 11 Jun 2021 Preclinical development is still ongoing in Germany (VAXIMM pipeline, June 2021)
- 28 Dec 2018 No recent reports of development identified for preclinical development in Cancer in Germany (PO)